Strategic partnerships OneOme has a history of collaborating with healthcare technology and services firms (for example Tabula Rasa Healthcare) to integrate pharmacogenomics into patient care, indicating a receptiveness to co-developed solutions and channel partnerships that can expand RightMed adoption.

Lab and data capabilities With an in-house CLIA-certified, CAP-accredited lab and advanced genetic insights, there is an opportunity to sell end-to-end pharmacogenomics workflows to health systems seeking compliant, integrated testing and decision-support within EHR or patient care pathways.

Cost and outcomes focus RightMed positioning emphasizes cost reduction and improved outcomes through personalized prescriptions, suggesting sales leverage with payers and health systems pursuing value-based care, formulary optimization, and reduced adverse drug events.

Global expansion readiness As a precision medicine leader aiming to influence prescriptions globally, there are upsell opportunities with international health networks, academic centers, and multi-site systems looking to standardize pharmacogenomic testing across campuses.

Gene-driven services The company’s pharmacogenomics test and analytics suite presents a clear cross-sell path to healthcare IT ecosystems (EMR/EHR, analytics platforms, provider portals) and to organizations seeking to embed genomic insights into clinical decision support and population health programs.